The TASS media network reported today the recombinant human adenoviral-based, two-part Sputnik M Vaccine for adolescents had been approved for use in Russia.
The Deputy Director-General of the Gamaleya Research Institute of Epidemiology and Microbiology Denis Logunov stated at a press conference on November 24, 2021, "The use of the Sputnik M vaccine by people twelve to 17 years was authorized today.’
Read More
